Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 505-510

  Neven, P ^a   Paridaens, R ^a   Amant, F ^a   Wildiers, H ^a   Berteloot, P ^a   Leunen, K ^a   Smeets, A ^a   Weltens, C ^a   Van Den Bogaert, W ^a   Van Limbergen, E ^a   Christiaens, M R ^a   Vergote, I ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROEXEMESTANE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DRUG METABOLITE; EXEMESTANE; LETROZOLE; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ARTHRALGIA; BONE; BONE PAIN; BREAST CANCER; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FRACTURE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIBIDO DISORDER; MEMORY DISORDER; MUSCULOSKELETAL PAIN; MYALGIA; NIGHT SWEAT; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SLEEP DISORDER; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA IRRITATION; VAGINAL DRYNESS; VASCULAR DISEASE; VERBAL MEMORY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 33748776804     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00682.x     Document Type: Conference Paper

References (30)

1. Winer EP, Hudis C, Burstein HJ et al. ASCO technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
3. Punglia RS, Kuntz KM, Winer EP et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005;23:5178-87.
4. Cuzick J, Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer [abstract]. Proc ASCO 2005;23:43s. Abstract 658.
5. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
6. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
7. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
8. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-7.
9. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
10. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
11. Jakesz R on behalf of ABCSG collaborators. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc ASCO 2005;23:10s.
12. Jakesz R, Gnant M, Greil R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8 [abstract]. Breast Cancer Res Treat 2005;94(Suppl. 1):S10. Abstract 13.
13. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7.
14. Viale G, Regan M, Dell'Orto P et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptorpositive breast cancer [abstract]. Breast Cancer Res Treat 2005; 94(Suppl. 1):S13-S14. Abstract 44.
15. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer tot anastrozole later 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in ABCSG Trial 8 and the ARNO Trial 95 [abstract]. Breast Cancer Res Treat 2004;88(Suppl. 1):S7. Abstract 2.
16. Jonat W, Gnant M, Boccardo F et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial [abstract]. Breast Cancer Res Treat 2005;94(Suppl. 1):S11. Abstract 18.
17. Coombes RC, Hall E, Snowdon CF et al. The IES: a randomized trial in postmenopausal patients with early breast cancer who remain disease free after two or three years of tamoxifen. An updated survival analysis. Breast Cancer Res Treat 2004;88(Suppl. 1):S7. Abstract 3.
18. Lønning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:1-12.
19. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on BMD in women completing ≥5 years of adjuvant tamoxifen: NCIC MA.17b [abstract]. Breast Cancer Res Treat 2004; 88(Suppl. 1):S36. Abstract 404.
20. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-15.
21. Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
22. Fallowfield L, Cella D, Cuzick J et al. Quality of life of post-menopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261-71.
23. Fallowfield L, Price MH, Hall E et al. Intergroup Exemestane Study: results of the quality of life sub-protocol. Breast Cancer Res Treat 2004;88(Suppl. 1):abstract 4.
24. Asmar L, Cantrell J, Vukelja S et al. Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study [abstract]. Breast Cancer Res Treat 2005;94(Suppl. 1):S97. Abstract 2039.
25. Duffy SR, Distler W on behalf of ATAC-trialists. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial [abstract]. Breast Cancer Res Treat 2005;94(Suppl. 1):S103. Abstract 2056.
26. Duffy S, Jackson TL, Landsdown et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545-53.
27. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane in the Intergroup Exemestane Study: 2 year BMD and bone biomarker data [abstract]. Breast Cancer Res Treat 2005;94(Suppl. 1): S233. Abstract 5076.
28. Brufsky A, Harker W, Beck J et al. Zoledronic acid effectively inhibits cancer treatment-induced bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 12 mos BMD results of the Z-FAST trial [abstract]. Proc ASCO 2005;(Suppl. 1):12S. Abstract 533.
29. Gnant M, Kakesz R, Mlineritsch B et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG Trial 12) [abstract]. Breast Cancer Res Treat 2004;88(Suppl. 1):S8-S9. Abstract 6.
30. Demonty G. Treatment guidelines for adjuvant breast cancer are moving towards double standards: one for the rich and one for the poor. J Clin Oncol 2005;23:9436-7.